Divalproex Sodium Tablet, Delayed Release
Product Images NDC 55154-4154

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55154-4154). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bag Label (5e59609f D79d 414b A6fc 7efb1ba5b200 00)

Bag Label (5e59609f D79d 414b A6fc 7efb1ba5b200 00)
Divalproex sodium delayed-release tablets, USP are available in a package of 10 tablets, with each tablet containing 500mg of Valproic Acid. The tablets are pink in color and have "798" imprinted with black ink on one side for identification purposes. A prescription is required to obtain the medication, and it is advised to refer to the product insert for dosage, precautions, and warnings. The medication is manufactured by Sun Pharmaceutical Industries Ltd in Gujarat, India, and distributed by its subsidiary Sun Pharmaceutical Industries Inc, and Major Pharmaceuticals, which is distributed by Cardinal Health, all in the USA. The medication should be stored at temperatures between 20° to 25°C (68° to 77°F), with controlled excursions allowed to 15° to 30°C (59° to 86°F). The packaging is light-resistant and dispensed with a medication guide. The unit dose packaging is not considered child-resistant and is intended for institutional use only.*
FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)
FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)
This is a graph figure showing the reduction in CPS rate for patients receiving DVPX compared to placebo. The graph shows percentages ranging from -100% to 100% with the CPS rate reduction expressed as positive percentages and worsening expressed as negative percentages. The horizontal axis shows the percentage of patients and the vertical axis shows the improvement, no change, or worsening of the CPS rate reduction. There is no additional information available in the text.*
FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)
FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)
FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Spl-divalproex-structure (Spl Divalproex Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.